Latest Industry Insights

Our ability to treat disorders of the body has advanced significantly in the 21st century. But that progress has not been matched by new therapies for psychiatric conditions. atai Life Sciences, a clinical-stage biopharmaceutical company, recently launched a new company that aims to correct that imbalance.

Technology Networks recently spoke with Jakob Dupont, head of global research & development at Atara Bio, to learn more about the company’s novel allogeneic EBV T-cell platform and discover how it’s enabling a differentiated approach to allogeneic cell therapy.

In this interview, we speak to Dr. Antal Szalay, CEO of Ultimate Medicine, about how his company helped establish that a microbiome metabolite can cause age-related memory loss.

Recent legislation changes by Health Canada have seen psychedelics become easier to prescribe for a range of mental health conditions. We spoke to Alexander Somjen, CEO of Origin Therapeutics, to find out what the impact of these changes will be for physicians, patients and providers.

Technology Networks spoke to Dr. Mark Kotter, CEO and founder of bit.bio to learn about opti-ox™ and the development, benefits and applications of ioSkeletal Myocytes.

Technology Networks had the pleasure of speaking with Saul Kato, the CEO of Herophilus, to learn more about how the company plans to reinvent neuro drug discovery, by combining human brain models, scaled biology and machine learning to decode brain disease.

Brain-computer interface (BCI) developer Blackrock Neurotech has announced that its MoveAgain BCI has received Breakthrough Device designation from the US Food and Drug Administration (FDA). To find out more, we spoke with Blackrock’s chairman and president, Florian Solzbacher.

We spoke to co-founder and executive chairman, Ronan Levy, to find out more about Field Trip’s approach to psychedelic therapy and why 2021 has been such a significant year in psychedelics.

The revival of psychedelic medicine is well underway. We spoke with Small Pharma CEO Peter Rands to discuss the unique features of the psychedelic DMT and updates from the company’s latest trials.

Poor mental health is a growing burden on global healthcare systems. In this opinion piece, Compass Pathways chief medical officer Professor Guy Goodwin reviews currently available treatments options and the results from his company's new clinical trial into the efficacy of the psychedelic psilocybin in treating mental health conditions.